Quantcast

Industry news that matters to you.  Learn more

Genewiz, Inc. Announces Collaboration with BeiGene, Ltd.

GENEWIZ, Inc., leading global genomics service provider, recently announced a collaboration with BeiGene, a biotechnology company focused on the discovery and development of innovative oncology treatment. The two companies will work together to accelerate cancer biomarker discovery, which will later aid drug target identification.

Headquartered in Beijing, BeiGene has established more than one hundred patient-derived primary tumor models in-house as part of their portfolio of oncology target therapies in early stage development. Utilizing OncoGxOne™ Discovery cancer panels, BeiGene will have the ability to identify and understand genetic variations in prevalent cancers throughout China and the Asia-Pacific region.

“Our collaboration with GENEWIZ and application of the OncoGxOne™ cancer panels will enable characterization of primary tumor models at the genetic level, with a focus on aberrations in cancer related genes,” stated Dr. Lai Wang, Head of Discovery Biomarkers, BeiGene.

“Due to the unique ability to detect aberrations including gene fusions and copy number variance (CNV), using OncoGxOne™ Discovery cancer panels we have capabilities to identify novel mutations present in BeiGene’s primary cancer tumor models,” commented Dr. Guanghui Hu, Vice President of Translational Genomics. “Later, this invaluable information can be used for cancer diagnosis and treatment, which will have a direct impact on patient treatment and quality of life.”

“We believe that this collaboration will strongly support our translational research and biomarker discovery,” asserted Dr. Wang.

Source: Genewiz

Veridex and LabCorp Agreement Brings CellSearch CTC Test to China

Veridex, LLC recently announced an agreement with LabCorp Clinical Trials that makes the CELLSEARCH® circulating tumor cell (CTC) test available for researchers conducting clinical trials in China. This marks the first clinical reference laboratory in China that offers CTC testing and comes on the heels of China’s State Food & Drug Administration approval of CELLSEARCH® as an in vitro diagnostic to manage patients with metastatic breast cancer.

EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company, recently announced the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study. Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway. This study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute. More information about the clinical trial can be found at www.ClinicalTrials.gov.

Qiagen Teams with China’s Lepu Medical to Provide Rapid Diagnosis of Heart Attacks Using Point of Need Testing

Qiagen N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced an agreement with Lepu Medical Technology (Beijing) Co., Ltd., a leading medical device company in China, to provide Qiagen’s ESEQuant Lateral Flow System for use in emergency rooms with Lepu’s tests for cardiac markers that diagnose acute myocardial infarction (heart attack). The agreement expands Qiagen’s presence in China and adds a new point of need diagnostics application.

Pharmaron to Host Merck Serono Research and Development Laboratory in China

Pharmaron today announced a strategic partnership with Merck Serono, the biopharmaceutical division of Merck KGaA, Germany. In the framework of this partnership, Pharmaron’s new campus in the Beijing Economic and Technological Development Area (BDA) will serve as home to Merck Serono’s China R&D Laboratory. The focus of this laboratory will be clinical bioanalysis and biomarker characterization, allowing for the identification of gene mutations among the Chinese population, early detection of disease processes, and development of personalized medicines for cancer and neurodegenerative diseases.